ドイツの医師からメールが来た。
感謝の内容であった。
私の論文を読み、
カモスタットではなく、
家族全員分のフォイパンを個人的に入手したとのことである。
カモスタットを販売している日本のメーカーに怒りを覚えるとともに、
何とも言えない喜びを感じた。
ドイツでは、月曜からロックダウンとなると記されていた。
//////////////////////////////////////////////////////////////////////////
Dear Dr. Uno,
when I read your very interesting article in Intern Emerg Med
2020 Apr 29:1-2 I was glad to see that my thoughts about camostat
mesilate were shared by your publication.
In March I read in Datsche Ärzteblatt about the findings of
Hoffman et al of Göttingen that cm can prevent covid 19 virus from
entering lung cells and when I read that mice were protected by cm
of lethal corona virus infection and that cm is in use in Japan for some
30 years I thought a remedy for this devastating pandemia was found.
For me it is very disappointing that many clinical
trials were and are done with various drugs like chloroquine and remdesivir
which have no or little effect. I know that clinical trials with cm are done in
Aarhus in Denmark and in Yale, USA but results are expected only next year.
I believe that Camostat could be taken by infected people
under compassionate-use rule. But that dosen`t happen as far as I know so far
in Germany. Perhaps because Camostat mesilate is not known here and used for
chronic pancreatitis as you do it in Japan.
Have you got an idea why cm is not used for cover 19? Is it
too cheap to be interesting for pharmaceutical firms? Or do you use it in Japan
for Cover 19 patients?
I have ordered and got Foipan by our pharmacist for my family
and myself. But I think it would be worth while to try if it is effective
in as many humans as possible.
Germany will be in a lockdown by Monday and a remedy seems so
near but it is not used.
I am a retired physician and I have no other than humanitarian
and (private) scientific reasons for my e-mail to you. Perhaps you have
experience in Japan with cm in treating covid 19 patients.
I would be very glad to hear from you
Yours sincerely
Wolfgang Nieswandt
Dr. med.
Wolfgang Nieswandt
Nibelungenstr.42
64625 Bensheim
Germany
・・・・・・・・・・・・・・・・・・・・・・・
Dear Dr. Wolfgang Nieswandt
Thank you for your
letter.
I am a gastroenterologist. My
job is to perform endoscopy on 10-12 people a day. In Japan, only 10,000 to
20,000 PCR tests are performed daily, and endoscopic examinations must protect
all patients as positive. Therefore, I replace two protective suits, double
mask and double gloves, shoe cover, and face shield in each endoscopy.
I myself have never treated a
patient with COVID-19. However, I have pursued what I can do to deal with this
global misery. I read a paper by Hoffmann in Germany and believed that Japanese
drugs could prevent the spread of SARS-CoV-2. Therefore, I sent an email to
Hoffman and wrote a paper suggesting an effective amount of virus suppression.
Prior to the publication of this paper, I received an email from an Italian
researcher introduced by Hoffman. He contacted me to send the camostat to Italy
for a camostat clinical trial in Italy. Therefore, I contacted a Japanese
pharmaceutical company. However, it was rejected by a Japanese pharmaceutical
company. The reason was that camostat is an insurance-covered drug in Japan and
can only be used for pancreatitis and reflux esophagitis. Why are the Japanese
government and pharmaceutical companies not interested in camostat? That's
probably because the camostat is too cheap. Politicians and businesses may only
be interested in expensive drugs and vaccines.
I think the cause of COVID-19's
aggravation these days is gastrointestinal infections.
In particular, I think proton
pump inhibitor (PPI ) is involved in the susceptibility and severity of
infection.
Uno Y. Why does SARS-CoV-2
invade the gastrointestinal epithelium? Gastroenterology 2020; 159: 404-405.
https://immunology.sciencemag.org/content/5/47/eabc3582/tab-e-letters
And UCLA studies have confirmed
that oral PPI increases COVID-19 infection.
This study is proof that my
hypothesis was correct.
Almario CV, et al. Increased
risk of COVID-19 among users of proton pump inhibitors. Am J Gastroenterol.
2020 Aug 25
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473791/
Both ACE2 and TEMPRESS2 are
abundant in the intestine.
Sungnak W, No\at Med 2020
Dai YJ Ann Transl Med 2020
The characteristic of severe
acute respiratory syndrome caused by SARS-19 is the presence of GI symptoms.
COVID-19 remembers that in the
Wuhan pandemic in China, PPI was always used in ICU.
However, in the case of
President Trump, famotidine was used instead of PPI.
PPIs can be purchased in the
United States without a prescription, and Americans with reflux esophagitis may
use PPIs on a daily basis, which may be the reason why SARS-CoV-2 is the most
infected in the United States.
The combination of camostat and
famotidine may be more effective.
Logically, the amount that acts
on the gastrointestinal mucosa, that is, 200 mg of camostat three times a day,
is likely to reduce gastrointestinal infections of SARS-CoV-2. May reduce the
severity of COVID-19.
If possible, the use of PPIs
for COVID-19 in Germany should be banned. It has the potential to save many
Germans.
Thank you for your
consideration.
Best regards,
Yoshiharu
